Irritable Bowel Syndrome (IBS) Treatment Market Analysis

Dosage Form (Tablets, Liquid, Powder)

The tablets segment in the irritable bowel syndrome treatment market is expected to capture 68.2% of the revenue share by the end of 2037, owing to their convenience and dosage accuracy. Tablets are easy to consume and carry as they are available in accurate and precise dosages, which makes them a preferred choice for many patients. Tablets typically have a longer shelf life compared to other formulations such as liquid and powder. This portability and stability are making them more appealing to patients and driving their demand growth.

The growing trend towards self-medication and over-the-counter availability for certain IBS drugs is making tablets a more accessible option for patients seeking immediate relief.

Distribution Channel (Brick & Mortar, E-commerce)

The brick and mortar segment is estimated to hold 67.5% of the global irritable bowel syndrome treatment market share through 2037. The easy accessibility is one of the prime reasons driving the sales of irritable bowel syndrome drugs through brick and mortar pharmacies. Physical pharmacies are easily accessible for patients who require immediate relief or ongoing management of irritable bowel syndrome symptoms. Many patients prefer to consult with a pharmacist face to face especially when dealing with sensitive health issues.

Also, many IBS patients rely on insurance coverage for prescription medications, brick and mortar pharmacies can facilitate the processing of insurance claims, making them a prime preference for medicine distribution. The sales of irritable bowel syndrome drugs through brick and mortar distribution channels were valued at USD 2.0 billion in 2023.

Our in-depth analysis of the irritable bowel syndrome treatment market includes the following segments: